Luminor药物涂层球囊与iVolution支架联合治疗TASC C/D股腘动脉病变的24个月结局
T.I.N.T.I.N.试验在比利时多中心前瞻性非随机纳入100例TASC C/D股腘动脉病变患者,评估Luminor药物涂层球囊联合iVolution自膨胀裸金属支架的安全性与疗效。12个月和24个月免于临床驱动靶病变血运重建率分别为94.6%和89.6%,12个月一期通畅率90.5%,结论为联合治疗安全有效。
要点
- Luminor药物涂层球囊联合iVolution支架治疗TASC C/D股腘动脉病变24个月安全有效。
- 12个月免于CD-TLR为94.6%,24个月为89.6%,12个月一期通畅率90.5%。
- 与仅用裸金属支架相比,紫杉醇涂层球囊预扩张可能改善1年和2年疗效。
核心结论
- Luminor药物涂层球囊后植入iVolution支架治疗股腘动脉病变在24个月内安全有效。
研究设计与样本
- T.I.N.T.I.N.试验为医生发起的、前瞻性、非随机、多中心研究,在比利时开展,纳入100例患者。
- 研究评估Luminor药物涂层球囊联合iVolution自膨胀支架治疗TASC C和D股腘动脉病变的安全性与疗效。
主要发现
- 患者平均年龄73.5±9.4岁,男性占67.0%。
- 12个月和24个月免于CD-TLR分别为94.6%(95% CE: 90.0-99.2)和89.6%(95% CE: 83.2-96.0)。
- 12个月一期通畅率为90.5%(95% CE: 84.2-96.8)。
- 1年和2年生存率分别为92.8%(95% CE: 87.8-97.8)和82.0%(95% CE: 74.2-89.8),无死亡与手术或器械相关。
临床怎么用
- 对于复杂股腘动脉病变,Luminor药物涂层球囊联合iVolution支架可作为旁路手术、覆膜自膨胀支架和药物洗脱支架之外的额外治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is evidence that the treatment of symptomatic femoropopliteal disease with a drug-coated balloon (DCB) effectively inhibits restenosis. However for longer and more complex lesions, "bailout" remains stenting almost inevitable. Although the combination therapy of DCBs and modern bare metal stent (BMS) has not been widely studied, there are indications that this combination therapy is doing better than BMS alone and could be a potential alternative for drug-eluting stent treatment. OBJECTIVE: The aim of this study is to evaluate the long-term outcome of the combination therapy with the Luminor DCB and the iVolution stent of iVascular for the treatment of long femoropopliteal lesions Transatlantic InterSociety Consensus (TASC) C and D. METHODS: The T.I.N.T.I.N. trial is a physician-initiated, prospective, non-randomized, multicenter trial conducted in Belgium, investigating the safety and efficacy of the treatment with the Luminor DCB and the iVolution self-expanding stent in 100 patients. The primary efficacy endpoint was freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months. The key secondary endpoints were primary patency at 12 months, CD-TLR at 24 months, and survival at 12 and 24 months. RESULTS: Participants had a mean age of 73.5 ± 9.4 years, with 67.0% being male participants. Sixty-two percent of the patients suffered from severe claudication (Rutherford 3) and 26.0% had limb-threatening ischemia (Rutherford 5). Freedom from CD-TLR at 12 and 24 months was 94.6% (95% CE: 90.0-99.2) and 89.6% (95% CE: 83.2-96.0), respectively. The primary patency rate at 12 months was 90.5% (95% CE: 84.2-96.8). Survival rate at 1 and 2 years was 92.8% (95% CE: 87.8-97.8) and 82.0% (95% CE: 74.2-89.8), respectively. None of the causes of death were procedure or device related. CONCLUSION: The combination of a Luminor DCB followed by an iVolution stent implantation resulted in safe and effective outcomes in the treatment of femoropopliteal lesions for up to 24 months. Adding paclitaxel to the bare nitinol stent platform by predilating with a Luminor DCB appears to improve efficacy at 1 and 2 years compared to the use of BMSs only, as observed in the precursor Evolution study.Clinical ImpactThis study proofs that especially in long and complex femoropopliteal lesions (full cohort of 100 patients instead of a subanalysis in a small subgroup with risk of biases), a combination therapy of a Paclitaxel coated balloon and a modern bare metal stent offers high levels of safety and efficacy up to 2 years. For clinicians it means that beside bypass surgery, covered self-expandable stents and drug eluting stents, they have an extra treatment option in the armamentarium for complex vascular disease in this anatomic area. Depending on personal preferences, reimbursement systems and device availabilities they can opt for one of these methods.
引用
- Deloose K, Drudi L, Verbist J, et al. Safety and Efficacy of Treatment With the Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Atherosclerotic Disease: 12 and 24-Month Outcome of the T.I.N.T.I.N. Physician-Initiated Trial. J Endovasc Ther. 2025. PMID: 40682293. doi:10.1177/15266028251350025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。